DRRX 241220 2.00C (DRRX241220C2000) Stock Options, News & Quotes

US OptionsDetailed Quotes

DRRX241220C2000

Watchlist

0.10
0.000.00%

15min DelayTrading Nov 11 12:47 ET

0.00High0.00Low

Intraday

5D
Daily

News

US Manufacturing Index Rises To 43, Highest Since 2020
Business TodayNov 16 02:13 ET
Durect | 10-Q: Q3 2024 Earnings Report
SECNov 14 16:09 ET · Announcements
Northland Securities Maintains Durect(DRRX.US) With Buy Rating, Maintains Target Price $8.5
Moomoo NewsNov 14 09:31 ET · Ratings
Northland Securities Sticks to Its Buy Rating for Durect (DRRX)
TipRanksNov 14 08:56 ET · Ratings
Oppenheimer Maintains Durect(DRRX.US) With Buy Rating, Maintains Target Price $5
Moomoo NewsNov 14 08:31 ET · Ratings
H.C. Wainwright Maintains Durect(DRRX.US) With Hold Rating
Moomoo NewsNov 14 06:33 ET · Ratings

Comments

Jaguar8

Oct 16 15:46

Form 4

$Durect (DRRX.US)$

Jaguar8

Sep 25 07:06

NEWS

$Durect (DRRX.US)$
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis
Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design
- Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint;topline results expected within two years of trial initiation
- Protocol for Phase 3 trial builds on data from the AHFIRM Phase 2b tr...

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

Trytosaveabit

May 21 07:02

News

$Durect (DRRX.US)$ Reuters· 1 min ago
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis